196 related articles for article (PubMed ID: 37095342)
1. Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials.
Yamamoto H; Yamada T; Miyazaki K; Yamashita T; Kato T; Ohara K; Nakamura Y; Akizawa T
Clin Exp Nephrol; 2023 Aug; 27(8):651-659. PubMed ID: 37095342
[TBL] [Abstract][Full Text] [Related]
2. Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study.
Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T
Am J Nephrol; 2021; 52(10-11):884-893. PubMed ID: 34569482
[TBL] [Abstract][Full Text] [Related]
3. Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies.
Yamamoto H; Taguchi M; Matsuda Y; Iekushi K; Yamada T; Akizawa T
BMJ Open; 2019 Jun; 9(6):e026704. PubMed ID: 31203242
[TBL] [Abstract][Full Text] [Related]
4. Effects of Molidustat in the Treatment of Anemia in CKD.
Macdougall IC; Akizawa T; Berns JS; Bernhardt T; Krueger T
Clin J Am Soc Nephrol; 2019 Jan; 14(1):28-39. PubMed ID: 30559105
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies.
Akizawa T; Macdougall IC; Berns JS; Bernhardt T; Staedtler G; Taguchi M; Iekushi K; Krueger T
Am J Nephrol; 2019; 49(4):271-280. PubMed ID: 30852574
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ
Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial.
Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T
Am J Nephrol; 2021; 52(10-11):871-883. PubMed ID: 34569489
[TBL] [Abstract][Full Text] [Related]
8. Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies.
Akizawa T; Taguchi M; Matsuda Y; Iekushi K; Yamada T; Yamamoto H
BMJ Open; 2019 Jun; 9(6):e026602. PubMed ID: 31203241
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial.
Singh AK; Cizman B; Carroll K; McMurray JJV; Perkovic V; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Wiecek A; Stankus N; Strutz F; Blackorby A; Cobitz AR; Meadowcroft AM; Paul G; Ranganathan P; Sedani S; Solomon S
JAMA Intern Med; 2022 Jun; 182(6):592-602. PubMed ID: 35377393
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.
Akizawa T; Nangaku M; Yonekawa T; Okuda N; Kawamatsu S; Onoue T; Endo Y; Hara K; Cobitz AR
Clin J Am Soc Nephrol; 2020 Aug; 15(8):1155-1165. PubMed ID: 32723804
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.
Warady BA; Meyer Reigner S; Tirodkar C; Drozdz D
Am J Kidney Dis; 2023 Jun; 81(6):684-694.e1. PubMed ID: 36587890
[TBL] [Abstract][Full Text] [Related]
12. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.
Saglimbene VM; Palmer SC; Ruospo M; Natale P; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD009904. PubMed ID: 28782299
[TBL] [Abstract][Full Text] [Related]
13. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
Palmer SC; Saglimbene V; Mavridis D; Salanti G; Craig JC; Tonelli M; Wiebe N; Strippoli GF
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010590. PubMed ID: 25486075
[TBL] [Abstract][Full Text] [Related]
14. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
Singh AK; Carroll K; Perkovic V; Solomon S; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Więcek A; Blackorby A; Cizman B; Cobitz AR; Davies R; Dole J; Kler L; Meadowcroft AM; Zhu X; McMurray JJV;
N Engl J Med; 2021 Dec; 385(25):2325-2335. PubMed ID: 34739194
[TBL] [Abstract][Full Text] [Related]
15. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
Chertow GM; Pergola PE; Farag YMK; Agarwal R; Arnold S; Bako G; Block GA; Burke S; Castillo FP; Jardine AG; Khawaja Z; Koury MJ; Lewis EF; Lin T; Luo W; Maroni BJ; Matsushita K; McCullough PA; Parfrey PS; Roy-Chaudhury P; Sarnak MJ; Sharma A; Spinowitz B; Tseng C; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Eckardt KU;
N Engl J Med; 2021 Apr; 384(17):1589-1600. PubMed ID: 33913637
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.
Eckardt KU; Agarwal R; Aswad A; Awad A; Block GA; Bacci MR; Farag YMK; Fishbane S; Hubert H; Jardine A; Khawaja Z; Koury MJ; Maroni BJ; Matsushita K; McCullough PA; Lewis EF; Luo W; Parfrey PS; Pergola P; Sarnak MJ; Spinowitz B; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Zwiech R; Chertow GM
N Engl J Med; 2021 Apr; 384(17):1601-1612. PubMed ID: 33913638
[TBL] [Abstract][Full Text] [Related]
17. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
Akizawa T; Iwasaki M; Yamaguchi Y; Majikawa Y; Reusch M
J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693
[TBL] [Abstract][Full Text] [Related]
18. Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial.
Hayashi T; Maruyama S; Nangaku M; Narita I; Hirakata H; Tanabe K; Morita S; Tsubakihara Y; Imai E; Akizawa T;
Clin J Am Soc Nephrol; 2020 May; 15(5):608-615. PubMed ID: 32245781
[TBL] [Abstract][Full Text] [Related]
19. Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
Akizawa T; Macdougall IC; Berns JS; Yamamoto H; Taguchi M; Iekushi K; Bernhardt T
Nephron; 2019; 143(4):243-254. PubMed ID: 31387097
[TBL] [Abstract][Full Text] [Related]
20. Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis.
Sarnak MJ; Agarwal R; Boudville N; Chowdhury PCP; Eckardt KU; Gonzalez CR; Kooienga LA; Koury MJ; Ntoso KA; Luo W; Parfrey PS; Vargo DL; Winkelmayer WC; Zhang Z; Chertow GM
Nephrol Dial Transplant; 2023 Sep; 38(10):2358-2367. PubMed ID: 37096396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
